PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
PhaseBio Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
PhaseBio Pharmaceuticals reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, three executives at PhaseBio Pharmaceuticals received on average a compensation package of $910.6K, a 80% increase compared to previous year.
Average pay of disclosed executives at PhaseBio Pharmaceuticals
Jonathan P. Mow, Chief Executive Officer, received $1.2M in total, which increased by 102% compared to 2018. 43.58% of Mow's compensation, or $524.3K, was in option awards. Mow also received $232.5K in non-equity incentive plan, $436.2K in salary, as well as $10.1K in other compensation.
John Lee, Chief Medical Officer, received a compensation package of $780.9K, which increased by 56% compared to previous year. 50.65% of the compensation package, or $395.5K, was in salary.
John P. Sharp, Chief Financial Officer, earned $747.9K in 2019, a 61% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 24, 2020.